Fast Track Designation recognizes both the urgent need for new therapies in pMN and the compelling early clinical activity generated to date with budoprutug,” said Edgar Charles, M.D., Chief Medical ...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ...

Climb Bio on Tuesday said there are currently no FDA-approved treatments for pMN, which affects about 75,000 people in the U.S. and can lead to chronic or end-stage kidney disease, requiring dialysis ...

Budoprutug is an investigational, humanized monoclonal antibody designed to selectively target and bind to CD19 antigen on B cells.

The FDA granted fast track designation to PAS-004, a macrocyclic MEK inhibitor, for NF1-associated plexiform neurofibromas ...

FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in ...

The FDA has granted Fast Track Designation to CTIM-76, a claudin-6 (CLDN6) x CD3 T cell engaging bispecific antibody, for the ...

Please provide your email address to receive an email when new articles are posted on . Nipocalimab is a potentially steroid sparing, immunoselective treatment designed to block FcRn and target IgG ...

— QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical trials for treatment of Netherton Syndrome — — Fast Track Designation follows Pediatric Rare Disease and Orphan ...

Please provide your email address to receive an email when new articles are posted on . VTx-002 targets proteins that play a significant role in neurodegenerative disease. Enrollment in and ...

ADCE-D01 targets the uPARAP protein in sarcomas, delivering medication directly to cancer cells, showing promise in early studies. The ADCElerate1 trial evaluates ADCE-D01's safety, tolerability, ...